OACC

+ Watchlist + Portfolio

Oaktree Acquisition Corp. III Life Sciences

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $10.75
52-Week Range: $10.36 – $10.88
Market Cap: $264.26M
P/E (TTM): 38.39
EPS (TTM): 0.28
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.73
Debt/Equity: —
Total Debt: $11.82K
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: -14.40%
Enterprise Value: $262.85M

OACC Income statement, annual periods, in USD
USD	FY2025
Revenue	$0.00
Selling, General & Admin	$1.20M
Operating Expenses	$1.20M
Operating Income	-$1.20M
EBITDA	-$1.20M
Pretax Income	$7.29M
Net Income	$7.29M
Diluted EPS	0.30
Diluted Shares	24.58M

OACC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Selling, General & Admin	$444.80K	$269.81K	$225.58K	$255.50K	$456.54K
Operating Expenses	$444.80K	$269.81K	$225.58K	$255.50K	$456.54K
Operating Income	-$444.80K	-$269.81K	-$225.58K	-$255.50K	-$456.54K
EBITDA	-$444.80K	-$269.81K	-$225.58K	-$255.50K	-$456.54K
Pretax Income	$1.66M	$1.87M	$1.97M	$1.79M	$1.39M
Net Income	$1.66M	$1.87M	$1.97M	$1.79M	$1.39M
Diluted EPS	0.07	0.08	0.08	—	0.06
Diluted Shares	24.58M	24.58M	24.58M	—	24.58M

OACC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.28M	$1.39M	$1.33M	$1.43M	$1.28M
Current Assets	$1.48M	$1.56M	$1.48M	$1.55M	$1.42M
Total Assets	$197.24M	$199.18M	$201.25M	$203.11M	$204.83M
Current Liabilities	$1.06M	$1.12M	$1.23M	$1.30M	$1.62M
Total Debt	$11.82K	$11.82K	$11.82K	$11.82K	$11.82K
Total Liabilities	$8.08M	$8.14M	$8.25M	$8.32M	$8.64M
Retained Earnings	-$6.52M	-$6.54M	-$6.77M	-$6.77M	-$7.23M
Shareholders' Equity	$189.16M	$191.04M	$193.00M	$194.79M	$196.19M
Working Capital	$423.96K	$441.91K	$254.09K	$248.59K	-$207.95K

OACC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$75.56K	-$146.12K	-$56.52K	-$143.88K	-$158.03K
Free Cash Flow	-$75.56K	-$146.12K	-$56.52K	-$143.88K	-$158.03K
Investing Cash Flow	—	—	$0.00	$250.00K	—
Net Change in Cash	-$75.56K	$103.88K	-$56.52K	$106.12K	-$158.03K

Market Snapshot

About

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to effect a merger or business combination in the life sciences sector. The SPAC is sponsored by Oaktree Capital Management.

USD	FY2025
Operating Cash Flow	-$422.08K
Free Cash Flow	-$422.08K
Investing Cash Flow	$500.00K
Financing Cash Flow	$0.00
Net Change in Cash	$77.92K